Cargando…

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes

Obesity is a major public health problem worldwide, and it is associated with many diseases and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces an immense variety of adipokines. Leptin is the first identified adipokine which plays a crucial role in the regulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szekeres, Zsolt, Sandor, Barbara, Bognar, Zita, Ramadan, Fadi H. J., Palfi, Anita, Bodis, Beata, Toth, Kalman, Szabados, Eszter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002958/ https://www.ncbi.nlm.nih.gov/pubmed/36901837 http://dx.doi.org/10.3390/ijms24054405

Ejemplares similares

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

Examination of Self-Esteem, Body Image, Eating Attitudes and Cardiorespiratory Performance in Adolescents
por: Petrovics, Peter, et al.
Publicado: (2021)

Association between Obesity and Overweight and Cardiorespiratory and Muscle Performance in Adolescents
por: Petrovics, Peter, et al.
Publicado: (2020)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Effects of Moderate Aerobic Exercise Training on Hemorheological and Laboratory Parameters in Ischemic Heart Disease Patients
por: Sandor, Barbara, et al.
Publicado: (2014)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
por: Anton, Irina Claudia, et al.
Publicado: (2022)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
por: McGill, Janet B.
Publicado: (2014)

Impact of home- and center- based physical training program on cardio-metabolic health and IGF-1 level in elderly women
por: Praksch, Dora, et al.
Publicado: (2019)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Publicado: (2022)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
por: Saad, Ranin, et al.
Publicado: (2022)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
por: Pennig, Jan, et al.
Publicado: (2019)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
por: Xu, Yixiang, et al.
Publicado: (2023)

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
por: Iannantuoni, Francesca, et al.
Publicado: (2019)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Involvement of Mitochondrial Mechanisms in the Cytostatic Effect of Desethylamiodarone in B16F10 Melanoma Cells
por: Ramadan, Fadi H. J., et al.
Publicado: (2020)

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes
por: Cheng, Sam Tsz Wai, et al.
Publicado: (2016)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(−/−) mice
por: Adingupu, Damilola D., et al.
Publicado: (2019)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice
por: Choi, Jungmi, et al.
Publicado: (2023)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model
por: Riba, Adam, et al.
Publicado: (2017)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamiodarone on 4T1 Triple-Negative Breast Cancer Line
por: Gallyas, Ferenc, et al.
Publicado: (2022)

The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
por: Ha, Chae-Myeong, et al.
Publicado: (2019)

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
por: Cheng, Lan, et al.
Publicado: (2022)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
por: Aragón-Herrera, Alana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e55bh7gpsogbni25gs8lvt1g0j